Merck & Co. stock falls 36.58 percent year to date

Published on 09/22/2026 at 14:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Merck & Co. stock closed at USD 143.76 on September 15, 2026, down 0.17 percent. Revenue reached USD 66.57 billion trailing twelve months, up 4.6 percent.

Photorealistic wide-angle view of a modern oncology research laboratory. A scientist in white lab coat examines cancer cell slides under a fluorescence microscope. Amber glass vials with pharmaceutical compounds line the stainless steel bench. Biosafety c — Merck US58933Y1055 Onkologie-Labor: Wissenschaftler am Mikroskop analysiert Krebszellen, mehrere Wirkstoff-Vials stehen auf der Werkbank, Illustration mit AI erstellt.

Merck & Co. (ISIN US58933Y1055) closed at USD 143.76 on the NYSE on September 15, 2026, down 0.17 percent from the prior close of USD 144.00. The year-to-date decline was 36.58 percent, making the share performance the clearest current signal for investors.

Stock remains below yearly high

The September 15 quotation stood within a 52-week range of USD 77.58 to USD 156.92, leaving the stock USD 13.16 below its yearly high. Market capitalization was USD 357.37 billion, while volume reached 4.67 million shares against a 65-day average of 10.38 million.

The valuation picture is mixed: the trailing price-to-earnings ratio was 115.06 on September 15, 2026, while the forward ratio was 17.32 in the latest available overview. That gap reflects the difference between reported earnings and the earnings base used for forward valuation.

Revenue grows while earnings contract

Merck & Co. generated USD 66.57 billion in trailing-twelve-month revenue, an increase of 4.6 percent in the latest reported data. Net income was USD 3.17 billion, down 80.7 percent, and earnings per share stood at USD 1.27, down 80.4 percent.

For historical comparison, fiscal-year 2025 revenue was USD 65.01 billion, up 1.31 percent from USD 64.17 billion in fiscal year 2024, while earnings rose 6.64 percent to USD 18.25 billion. The comparison shows that revenue growth continued, but the latest trailing figures carry a much sharper earnings decline.

Next results are scheduled for October

Merck & Co. is listed on the NYSE under ticker MRK and operates across prescription medicines, vaccines and animal health. The next earnings date listed in the current market overview is October 29, 2026, giving investors a defined checkpoint for testing the gap between current earnings and forward valuation.

Merck stock closes at USD 143.76

Merck & Co. stock closed at USD 143.76 on the NYSE on September 15, 2026, with a daily change of negative 0.17 percent. The shares were 8.38 percent below the 52-week high of USD 156.92, based on the same market-data snapshot.